Cargando…
CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells
Cisplatin (cis-diamminedichloroplatinum II [CDDP] ) is a well-known chemotherapeutic drug that has been used for the treatment of various types of human cancers, including head and neck cancer. Cisplatin exerts anticancer effects by causing DNA damage, replication defects, transcriptional inhibition...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226407/ https://www.ncbi.nlm.nih.gov/pubmed/32244823 http://dx.doi.org/10.3390/cancers12040856 |
_version_ | 1783534280366882816 |
---|---|
author | Chikuda, Junichiro Otsuka, Kurataka Shimomura, Iwao Ito, Kagenori Miyazaki, Hiroaki Takahashi, Ryou-u Nagasaki, Masahiro Mukudai, Yoshiki Ochiya, Takahiro Shimane, Toshikazu Shirota, Tatsuo Yamamoto, Yusuke |
author_facet | Chikuda, Junichiro Otsuka, Kurataka Shimomura, Iwao Ito, Kagenori Miyazaki, Hiroaki Takahashi, Ryou-u Nagasaki, Masahiro Mukudai, Yoshiki Ochiya, Takahiro Shimane, Toshikazu Shirota, Tatsuo Yamamoto, Yusuke |
author_sort | Chikuda, Junichiro |
collection | PubMed |
description | Cisplatin (cis-diamminedichloroplatinum II [CDDP] ) is a well-known chemotherapeutic drug that has been used for the treatment of various types of human cancers, including head and neck cancer. Cisplatin exerts anticancer effects by causing DNA damage, replication defects, transcriptional inhibition, cell cycle arrest, and the induction of apoptosis. However, drug resistance is one of the most serious problems with cancer chemotherapy, and it causes expected therapeutic effects to not always be achieved. Here, we analyzed global microRNA (miRNA) expression in CD44 standard form (CD44s)-expressing SAS cells, and we identified miR-629-3p as being responsible for acquiring anticancer drug resistance in head and neck cancer. The introduction of miR-629-3p expression inhibited apoptotic cell death under cisplatin treatment conditions, and it promoted cell migration. Among the computationally predicted target genes of miR-629-3p, we found that a number of gene expressions were suppressed by the transfection with miR-629-3p. Using a xenografting model, we showed that miR-629-3p conferred cisplatin resistance to SAS cells. Clinically, increased miR-629-3p expression tended to be associated with decreased survival in head and neck cancer patients. In conclusion, our data suggest that the increased expression of miR-629-3p provides a mechanism of cisplatin resistance in head and neck cancer and may serve as a therapeutic target to reverse chemotherapy resistance. |
format | Online Article Text |
id | pubmed-7226407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72264072020-05-18 CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells Chikuda, Junichiro Otsuka, Kurataka Shimomura, Iwao Ito, Kagenori Miyazaki, Hiroaki Takahashi, Ryou-u Nagasaki, Masahiro Mukudai, Yoshiki Ochiya, Takahiro Shimane, Toshikazu Shirota, Tatsuo Yamamoto, Yusuke Cancers (Basel) Article Cisplatin (cis-diamminedichloroplatinum II [CDDP] ) is a well-known chemotherapeutic drug that has been used for the treatment of various types of human cancers, including head and neck cancer. Cisplatin exerts anticancer effects by causing DNA damage, replication defects, transcriptional inhibition, cell cycle arrest, and the induction of apoptosis. However, drug resistance is one of the most serious problems with cancer chemotherapy, and it causes expected therapeutic effects to not always be achieved. Here, we analyzed global microRNA (miRNA) expression in CD44 standard form (CD44s)-expressing SAS cells, and we identified miR-629-3p as being responsible for acquiring anticancer drug resistance in head and neck cancer. The introduction of miR-629-3p expression inhibited apoptotic cell death under cisplatin treatment conditions, and it promoted cell migration. Among the computationally predicted target genes of miR-629-3p, we found that a number of gene expressions were suppressed by the transfection with miR-629-3p. Using a xenografting model, we showed that miR-629-3p conferred cisplatin resistance to SAS cells. Clinically, increased miR-629-3p expression tended to be associated with decreased survival in head and neck cancer patients. In conclusion, our data suggest that the increased expression of miR-629-3p provides a mechanism of cisplatin resistance in head and neck cancer and may serve as a therapeutic target to reverse chemotherapy resistance. MDPI 2020-04-01 /pmc/articles/PMC7226407/ /pubmed/32244823 http://dx.doi.org/10.3390/cancers12040856 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chikuda, Junichiro Otsuka, Kurataka Shimomura, Iwao Ito, Kagenori Miyazaki, Hiroaki Takahashi, Ryou-u Nagasaki, Masahiro Mukudai, Yoshiki Ochiya, Takahiro Shimane, Toshikazu Shirota, Tatsuo Yamamoto, Yusuke CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title | CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title_full | CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title_fullStr | CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title_full_unstemmed | CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title_short | CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells |
title_sort | cd44s induces mir-629-3p expression in association with cisplatin resistance in head and neck cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226407/ https://www.ncbi.nlm.nih.gov/pubmed/32244823 http://dx.doi.org/10.3390/cancers12040856 |
work_keys_str_mv | AT chikudajunichiro cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT otsukakurataka cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT shimomuraiwao cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT itokagenori cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT miyazakihiroaki cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT takahashiryouu cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT nagasakimasahiro cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT mukudaiyoshiki cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT ochiyatakahiro cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT shimanetoshikazu cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT shirotatatsuo cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells AT yamamotoyusuke cd44sinducesmir6293pexpressioninassociationwithcisplatinresistanceinheadandneckcancercells |